



US008731963B1

(12) **United States Patent**  
**Reardan et al.**

(10) **Patent No.:** **US 8,731,963 B1**  
(45) **Date of Patent:** **\*May 20, 2014**

- (54) **SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD** 4,976,351 A 12/1990 Mangini et al.  
5,737,539 A 4/1998 Edelson et al.  
5,845,255 A 12/1998 Mayaud  
5,924,074 A 7/1999 Evans  
(75) Inventors: **Dayton T. Reardan**, Shorewood, MN 5,963,919 A \* 10/1999 Brinkley et al. .... 705/28  
(US); **Patti A. Engel**, Eagan, MN (US); 6,021,392 A 2/2000 Lester et al.  
**Bob Gagne**, St. Paul, MN (US) 6,045,501 A 4/2000 Elsayed et al.  
6,055,507 A 4/2000 Cunningham  
(73) Assignee: **Jazz Pharmaceuticals, Inc.**, Palo Alto, CA (US) 6,112,182 A 8/2000 Akers et al.  
6,315,720 B1 11/2001 Williams et al.  
6,347,329 B1 2/2002 Evans  
(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. 6,564,121 B1 5/2003 Wallace et al.  
6,687,676 B1 2/2004 Denny  
(Continued)

This patent is subject to a terminal disclaimer.

FOREIGN PATENT DOCUMENTS

EP 0527027 A1 2/1993

(21) Appl. No.: **13/592,202**

OTHER PUBLICATIONS

(22) Filed: **Aug. 22, 2012**

"Advisory Committee Video on Xyrem, Oral Solution", (May 29, 2001), 9 minutes, 8 seconds.

Related U.S. Application Data

(Continued)

(63) Continuation of application No. 13/013,680, filed on Jan. 25, 2011, now abandoned, which is a continuation of application No. 12/704,097, filed on Feb. 11, 2010, now Pat. No. 7,895,059, which is a continuation of application No. 10/322,348, filed on Dec. 17, 2002, now Pat. No. 7,668,730.

Primary Examiner — Lena Najarian

(74) *Attorney, Agent, or Firm* — Schwegman Lundberg & Woessner, P.A.

(51) **Int. Cl.**  
**G06Q 10/00** (2012.01)

(52) **U.S. Cl.**  
USPC ..... 705/2; 705/3; 707/803

(58) **Field of Classification Search**  
USPC ..... 707/803; 705/2, 3  
See application file for complete search history.

(57) **ABSTRACT**


A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,556,342 A 1/1971 Guarr  
4,847,764 A 7/1989 Halvorson

**28 Claims, 16 Drawing Sheets**



(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,755,784	B2	6/2004	Williams et al.	
6,952,681	B2	10/2005	McQuade et al.	
7,058,584	B2	6/2006	Kosinski et al.	
7,668,730	B2	2/2010	Reardan et al.	
7,765,106	B2	7/2010	Reardan et al.	
7,765,107	B2	7/2010	Reardan et al.	
7,797,171	B2	9/2010	Reardan et al.	
7,895,059	B2	2/2011	Reardan et al.	
8,457,988	B1	6/2013	Reardan et al.	
8,589,182	B1	11/2013	Reardan et al.	
2001/0001144	A1	5/2001	Kapp	
2001/0042050	A1	11/2001	Fletcher et al.	
2001/0047281	A1	11/2001	Keresman, III et al.	
2002/0010661	A1	1/2002	Waddington et al.	
2002/0032581	A1	3/2002	Reitberg	
2002/0032582	A1	3/2002	Feeney, Jr. et al.	
2002/0042725	A1	4/2002	Mayaud	
2002/0042762	A1	4/2002	McQuade et al.	
2002/0052762	A1	5/2002	Kobylevsky et al.	
2002/0161607	A1	10/2002	Subich	
2002/0177232	A1	11/2002	Melker et al.	
2003/0033168	A1	2/2003	Califano et al.	
2003/0046110	A1	3/2003	Gogolak	
2003/0050731	A1 *	3/2003	Rosenblum	700/232
2003/0050802	A1	3/2003	Jay et al.	
2003/0074225	A1	4/2003	Borsand et al.	
2003/0093295	A1	5/2003	Lilly et al.	
2003/0110060	A1	6/2003	Clementi	
2003/0127508	A1	7/2003	Jones	
2003/0144876	A1	7/2003	Kosinski et al.	
2003/0160698	A1	8/2003	Andreasson et al.	
2003/0197366	A1	10/2003	Kusterbeck	
2003/0229519	A1	12/2003	Eidex et al.	
2003/0233256	A1	12/2003	Cardenas et al.	
2004/0008123	A1	1/2004	Carrender et al.	
2004/0019567	A1	1/2004	Herceg et al.	
2004/0019794	A1	1/2004	Moradi et al.	
2004/0078237	A1	4/2004	Kaafarani et al.	
2004/0107117	A1	6/2004	Denny	
2004/0117126	A1	6/2004	Fetterman et al.	
2004/0122712	A1	6/2004	Hill, Sr. et al.	
2004/0122713	A1	6/2004	Hill, Sr. et al.	
2004/0162740	A1	8/2004	Ericsson et al.	
2004/0176985	A1	9/2004	Lilly et al.	
2005/0090425	A1	4/2005	Reardan et al.	
2005/0216309	A1	9/2005	Reardan et al.	
2005/0222874	A1	10/2005	Reardan et al.	
2010/0138237	A1	6/2010	Reardan et al.	
2011/0119085	A1	5/2011	Reardan et al.	
2012/0209623	A1	8/2012	Reardan et al.	

## OTHER PUBLICATIONS

"An Interview with Orphan Medical about Xyrem", [http://www.talkaboutslepp.com/sleepdisorders/archives/Narcolepsy\\_xyrem\\_interview.htm](http://www.talkaboutslepp.com/sleepdisorders/archives/Narcolepsy_xyrem_interview.htm), (Feb. 12, 2001), 3 pgs.  
 "U.S. Appl. No. 10/322,348, Advisory Action mailed Feb. 5, 2007", 3 pgs.  
 "U.S. Appl. No. 10/322,348, Appeal Brief filed May 21, 2007", 32 pgs.  
 "U.S. Appl. No. 10/322,348, Examiner Interview Summary mailed Oct. 21, 2009", 3 pgs.  
 "U.S. Appl. No. 10/322,348, Final Office Action mailed Oct. 18, 2006", 14 pgs.  
 "U.S. Appl. No. 10/322,348, Final Office Action mailed Dec. 29, 2005", 11 pgs.  
 "U.S. Appl. No. 10/322,348, Non Final Office Action mailed Jun. 17, 2005", 26 pgs.  
 "U.S. Appl. No. 10/322,348, Non Final Office Action mailed Jun. 19, 2006", 18 pgs.  
 "U.S. Appl. No. 10/322,348, Non Final Office Action mailed Jun. 29, 2005", 12 pgs.  
 "U.S. Appl. No. 10/322,348, Notice of Allowance mailed Dec. 31, 2009", 16 pgs.

"U.S. Appl. No. 10/322,348, Preliminary Amendment mailed Sep. 30, 2004", 11 pgs.  
 "U.S. Appl. No. 10/322,348, Reply Brief filed Dec. 3, 2007", 4 pgs.  
 "U.S. Appl. No. 10/322,348, Response filed Jan. 17, 2007 to Final Office Action mailed Oct. 18, 2006", 17 pgs.  
 "U.S. Appl. No. 10/322,348, Response filed Mar. 29, 2006 to Final Office Action mailed Dec. 29, 2005", 11 pgs.  
 "U.S. Appl. No. 10/322,348, Response filed Aug. 8, 2006 to Non Final Office Action mailed Jun. 19, 2006", 10 pgs.  
 "U.S. Appl. No. 10/322,348, Response filed Sep. 29, 2005 to Non Final Office Action mailed Jun. 29, 2005", 19 pgs.  
 "U.S. Appl. No. 10/731,915, Non Final Office Action mailed Sug. 12, 2005", 22 pgs.  
 "U.S. Appl. No. 10/731,915, Non Final Office Action mailed Oct. 5, 2004", 21 pgs.  
 "U.S. Appl. No. 10/731,915, Non Final Office Action Response mailed Feb. 2, 2005", 17 pgs.  
 "U.S. Appl. No. 10/979,665, Non-Final Office Action mailed Nov. 17, 2009", 19 pgs.  
 "U.S. Appl. No. 10/979,665, Notice of Allowance mailed Apr. 30, 2010", 8 pgs.  
 "U.S. Appl. No. 10/979,665, Preliminary Amendment filed Jun. 22, 2006", 7 pgs.  
 "U.S. Appl. No. 10/979,665, Preliminary Amendment mailed Nov. 2, 2004", 3 pgs.  
 "U.S. Appl. No. 10/979,665, Response filed Mar. 11, 2010 to Non Final Office Action mailed Nov. 17, 2009", 13 pgs.  
 "U.S. Appl. No. 10/979,665, Response filed Jul. 14, 2009 to Restriction Requirement mailed Jun. 25, 2009", 8 pgs.  
 "U.S. Appl. No. 10/979,665, Restriction Requirement mailed Jun. 25, 2009", 7 pgs.  
 "U.S. Appl. No. 11/097,651, Examiner Interview Summary mailed May 27, 2010", 3 pgs.  
 "U.S. Appl. No. 11/097,651, Final Office Action mailed Nov. 12, 2009", 14 pgs.  
 "U.S. Appl. No. 11/097,651, Non-Final Office Action mailed Mar. 3, 2010", 19 pgs.  
 "U.S. Appl. No. 11/097,651, Non-Final Office Action mailed May 27, 2009", 21 pgs.  
 "U.S. Appl. No. 11/097,651, Notice of Allowance mailed Jul. 23, 2010", 9 pgs.  
 "U.S. Appl. No. 11/097,651, Preliminary Amendment mailed Apr. 1, 2005", 6 pgs.  
 "U.S. Appl. No. 11/097,651, Response filed Feb. 9, 2010 to Final Office Action mailed Nov. 12, 2009", 11 pgs.  
 "U.S. Appl. No. 11/097,651, Response filed Jun. 3, 2010 to Non Final Office Action mailed Mar. 3, 2010", 12 pgs.  
 "U.S. Appl. No. 11/097,651, Response filed Sep. 17, 2009 to Non Final Office Action mailed May 29, 2009", 10 pgs.  
 "U.S. Appl. No. 11/097,985, Non Final Office Action mailed Sep. 14, 2009", 22 pgs.  
 "U.S. Appl. No. 11/097,985, Notice of Allowance mailed Mar. 10, 2010", 11 pgs.  
 "U.S. Appl. No. 11/097,985, Preliminary Amendment mailed Apr. 1, 2005", 7 pgs.  
 "U.S. Appl. No. 11/097,985, Response filed Nov. 3, 2009 to Non Final Office Action mailed Sep. 14, 2009", 15 pgs.  
 "U.S. Appl. No. 11/097,985, Supplemental Notice of Allowability mailed Jun. 29, 2010", 3 pgs.  
 "U.S. Appl. No. 12/704,097, Non-Final Office Action mailed Sep. 24, 2010", 5 pgs.  
 "U.S. Appl. No. 12/704,097, Notice of Allowance mailed Dec. 21, 2010", 8 pgs.  
 "U.S. Appl. No. 12/704,097, Response filed Nov. 4, 2010 to Non Final Office Action mailed Sep. 24, 2010", 12 pgs.  
 "U.S. Appl. No. 13/013,680, Response filed Jun. 12, 2012 to Restriction Requirement mailed Dec. 14, 2011", 9 pgs.  
 "U.S. Appl. No. 13/013,680, Restriction Requirement mailed Dec. 14, 2011", 7 pgs.  
 "U.S. Appl. No. 13/013,680, Preliminary Amendment filed Jun. 13, 2012", 4 pgs.

(56)

## References Cited

## OTHER PUBLICATIONS

- "Civil Docket", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 2:10-CV-06108-ES-CLW), (Nov. 22, 2010), 15 pgs.
- "Complaint for Patent Infringement", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 10-6108 (ES) (CLW)), (Nov. 22, 2010), 14 pgs.
- "Diversion Prevention Through Responsible Distribution", NADDI Regional Training, (May 2001), 12 pages.
- "Diversion Prevention Through Responsible Distribution", NADDI Regional Training Tennessee, (Jun. 2001), 14 Pages.
- "Diversion Prevention Through Responsible Distribution", NADDI National Conference, (Nov. 2001), 15 pages.
- "Jazz Pharmaceuticals, Inc.'s Opening Markman Brief", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, United States District Court, District of New Jersey Civil Action No. 10-6108 (ES) (CLW), (Dec. 5, 2011), 34 pgs.
- "Jazz Pharmaceuticals, Inc.'s Responsive Markman Brief", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 10-6108 (ES) (CLW)), (Feb. 21, 2012), 41 pgs.
- "Joint Claim Construction and Prehearing Statement", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 10-6108 (ES) (CLW)), (Oct. 21, 2011), 31 pgs.
- "Letter dated Oct. 14, 2010 from Randall S. Wilson (Roxane Labs) to Bruce C. Cozadd (Jazz Pharmaceuticals)", Re: Patent Notice Pursuant to Section 505(b)(3)(B) [21 USC Sec. 355(b)(3)(B)], (Oct. 14, 2010), 11 pgs.
- "Letter from Theodora McCormick to Magistrate Judge Cathy L. Weldor", (w/ Exhibits), (Feb. 27, 2012), 60 pgs.
- "Letter from Theodora McCormick to Magistrate Judge Cathy L. Weldor", (w/ Exhibits), (Mar. 19, 2012), 104 pgs.
- "Letter from Theodora McCormick to Magistrate Judge Cathy L. Weldor", (Mar. 29, 2012), 4 pgs.
- "NASCSA National Conference", Orphan Medical, Inc., (Nov. 2000), 8 pgs.
- "Peripheral and Central Nervous System Drugs Advisory Committee", Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Holiday Inn, Bethesda, Maryland, (Jun. 6, 2001), 7 pages.
- "Preliminary Amendment pursuant to 37 CFR Sec. 1.115", U.S. Appl. No. 11/104,013, filed Apr. 12, 2005, 3 pgs.
- "Reply to Counterclaims", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 10-6108 (SDW) (MCA), (Feb. 7, 2011), 37 pgs.
- "Reply to Counterclaims", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 11-660 (SDW) (MCA) Lead Action CV-10-6108), (Apr. 18, 2011), 6 pgs.
- "Roxane Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 10-6108 (ES) (CLW), (Dec. 29, 2010), 21 pgs.
- "Roxane Laboratories, Inc.'s Initial Invalidity and Noninfringement Contentions Pursuant to Local Patent Rule 3.6", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 2:10-cv-06108 (SDW) (MCA)), (Apr. 14, 2011), 317 pgs.
- "Roxane Laboratories, Inc.'s Opening Markman Brief in Support of Its Claim Constructions", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 2:10-cv-06108 (ES) (CLW)), (Dec. 5, 2011), 37 pgs.
- "Roxane Laboratories, Inc.'s Responsive Markman Brief in Support of Its Claim Constructions", *Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.*, (United States District Court, District of New Jersey Civil Action No. 2:10-cv-06108 (ES) (CLW)), (Feb. 21, 2012), 27 pgs.
- "System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) Starter Kit", Celgene Corporation, (2001), 103 pgs.
- Ukens, C., "Specialty Pharmacy", *Drug Topics*, 144, (Jun. 5, 2000), 40-47.
- "U.S. Appl. No. 13/595,757, Non Final Office Action mailed Jan. 17, 2013", 6 pgs.
- "Markman Opinion, filed Sep. 14, 2012, in the case of *Jazz Pharmaceuticals, Inc.*, Plaintiff, *v. Roxane Laboratories, Inc.*, Defendant (United States District Court for the District of New Jersey, Civil 10-6108 ES)", 43 pgs.
- "Roxane Laboratories, Inc.'s Answer and Affirmative Defenses to Plaintiff's Complaint", (Jan. 4, 2013), 8 pgs.
- "Roxane Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint", (Mar. 9, 2011), 13 pgs.
- "Roxane Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint", (Jun. 1, 2011), 12 pgs.
- "Roxane Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint", (Nov. 9, 2012), 18 pgs.
- "Briefing Booklet for the Peripheral and Central Nervous System Drugs Advisory Committee Meeting", Orphan Medical, Inc., (Jun. 6, 2001), 353 pgs.
- "Civil Cover Sheet", *Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC*, (United States District Court, District of New Jersey, (Jan. 18, 2013), 2 pgs.
- "Complaint for Patent Infringement", *Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC*, (United States District Court, District of New Jersey, (Jan. 18, 2013), 17 pgs.
- "Controlled Substances Act", Drugs of Abuse, U.S. Department of Justice, Drug Enforcement Administration, (1997), 9 pgs.
- "Detailed Factual and Legal Basis of Non-Infringement and/or Invalidity", Amneal Pharmaceuticals, LLC, (Dec. 12, 2012), 3 pgs.
- "Detailed Factual and Legal Basis of Non-Infringement and/or Invalidity", Amneal Pharmaceuticals, LLC, (Dec. 7, 2012), 6 pgs.
- "Exhibits A-D", *Jazz Pharmaceuticals v. Amneal Pharmaceuticals, LLC*, (Jan. 18, 2013), 151 pgs.
- "Exhibits D-G", *Jazz Pharmaceuticals v. Amneal Pharmaceuticals, LLC*, (Jan. 18, 2013), 123 pgs.
- "Fed. R. Civ. P. Rule 7.1 Disclosure Statement", (Jan. 18, 2013), 2 pgs.
- "Making Good in Your Own Mail-Order Business", *Changing Times—The Kiplinger Magazine*, (Oct. 1980), 66-68.
- "Notice of Electronic Filing: Civil Initial Pleadings (Attorney/Credit Card) Use Case 33-1", US District Court, District of New Jersey [LIVE], (Jan. 18, 2013), 2 pgs.
- "Notice of Paragraph IV Certification Concerning ANDA 203631 for Sodium Oxybate Oral Solution, 500 mg/mL", Amneal Pharmaceuticals, LLC, (Dec. 7, 2012), 4 pgs.
- "Notice of Paragraph IV Certification Concerning ANDA 203631 for Sodium Oxybate Oral Solution. 500 mg/mL", Amneal Pharmaceuticals, LLC, (Dec. 12, 2012), 4 pgs.
- "Peripheral and Central Nervous System Drugs Advisory Committee—Transcript", Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Holiday Inn, Bethesda, Maryland, (Jun. 6, 2001), 381 pgs.
- "Xyrem Prescription and Distribution Process-Video Script", (Feb. 2, 2001), 10 pgs.
- Deutsch, Sheryl, "The Verification and Information-Gathering Process", *The Credentialing Handbook*, Aspen Publishers, Inc., (1999), 231-275.
- Mani, Ranjit, "Preliminary Clinical Safety Review of NDA No. 21196", Orphan Medical, Inc., (May 3, 2001), 122 pgs.
- "U.S. Appl. No. 13/595,676, Notice of Allowance mailed Sep. 17, 2013", 8 pgs.
- "Civil Cover Sheet", *Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC*, (United States District Court, District of New Jersey), (Sep. 12, 2013), 2 pgs.
- "Complaint for Patent Infringement with Exhibit A", *Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC*, (United States District Court, District of New Jersey), (Sep. 12, 2013), 76 pgs.

(56)

## References Cited

## OTHER PUBLICATIONS

- “Fed. R. Civ. P. Rule 7.1 Disclosure Statement”, *Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC*, (United States District Court, District of New Jersey), (Sep. 12, 2013), 2 pgs.
- “Notice of Electronic Filing: Civil Initial Pleadings (Attorney/Credit Card) Use Case 33-1”, *Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC*, (United States District Court, District of New Jersey [LIVE]), (Sep. 12, 2013), 1 pg.
- “U.S. Appl. No. 13/595,676, Response filed May 31, 2013 to Non Final Office Action mailed Mar. 21, 2013”, 14 pgs.
- “U.S. Appl. No. 13/595,676, Examiner Interview Summary mailed May 30, 2013”, 3 pgs.
- “Notice of Paragraph IV Certification”, Detailed Statement of the Factual and Legal Bases for Paragraph IV Patent Certification and Offer of Confidential Access, (Nov. 20, 2013), 190 pgs.
- Oxtoby, David W, et al., “”, Principles of Modern Chemistry, Fort Worth : Saunders College Pub., (1996), 52-56.
- “Civil Action No. 2:13-cv-00391-ES-SCM (consolidated)”, Defendant Amneal Pharmaceuticals, LLC’s Preliminary Invalidity Contentions (United States District Court of New Jersey), 182 pgs.
- “Civil Cover Sheet”, *Jazz Pharmaceuticals, Inc. v. Par Pharmaceuticals, Inc.*, (United States District Court, District of New Jersey), (Dec. 27, 2013), 1 pg.
- “Complaint for Patent Infringement”, *Jazz Pharmaceuticals, Inc. v. Par Pharmaceuticals, Inc.*, (United States District Court, District of New Jersey), (Dec. 27, 2013), 26 pgs.
- “Fed. R. Civ. P. Rule 7.1 Disclosure Statement”, *Jazz Pharmaceuticals, Inc. v. Par Pharmaceuticals, Inc.*, (United States District Court, District of New Jersey), (Dec. 27, 2013), 2 pgs.
- “Final Minutes: Peripheral and Central Nervous System Drugs Advisory Committee”, [Online]. Retrieved from the Internet: <URL: <http://www.fda.gov/ohrms/dockets/ac/01/minutes/3754m1.htm>>, (Jun. 6, 2001), 6 pgs.
- “Notice of Paragraph IV Certification”, Detailed Statement of the Factual and Legal Bases for Paragraph IV Patent Certification and Offer of Confidential Access, (Dec. 20, 2013), 190 pgs.
- “Orphan Medical Slides: Xyrem (sodium oxybate) oral solution”, Peripheral and Central Nervous System Drugs Advisory Committee Meeting, [Online]. Retrieved from the Internet: <URL: [http://www.fda.gov/ohrms/dockets/ac/01/slides/3754s1\\_01\\_orphanmedical/index.htm](http://www.fda.gov/ohrms/dockets/ac/01/slides/3754s1_01_orphanmedical/index.htm)>, (Jun. 6, 2001), 167 pgs.
- “Report on the Filing or Determination of an Action Regarding a Patent or Trademark”, *Jazz Pharmaceuticals, Inc. v. Par Pharmaceuticals, Inc.*, United States District Court, District of New Jersey Case No. 2:13-cv-07884-ES-JAD, (Dec. 27, 2013), 1 pg.
- “Slides: Pediatric Subcommittee of the Peripheral and Central Nervous system Drugs Advisory Committee”, [Online]. Retrieved from the Internet: <URL: <http://www.fda.gov/ohrms/dockets/ac/01/slides/3754s1.htm>>, (Jun. 6, 2001), 86 pgs.
- “Summons in a Civil Case”, *Jazz Pharmaceuticals, Inc. v. Par Pharmaceuticals, Inc.*, United States District Court, District of New Jersey Case No. 2:13-CV-07884-ES-JAD, (Dec. 31, 2013), 2 pgs.
- Oxtoby, David W, et al., Principles of Modern Chemistry, Fort Worth: Saunders College Pub., (1996), 52-56.
- U.S. Appl. No. 13/595,676, Non Final Office Action mailed Mar. 21, 2013, 16 pgs.
- U.S. Appl. No. 13/595,757, Examiner Interview Summary mailed Mar. 12, 2013, 3 pgs.
- U.S. Appl. No. 13/595,757, Notice of Allowance mailed Mar. 21, 2013, 68 pgs.
- U.S. Appl. No. 13/595,757, Response filed Mar. 7, 2013 to Non Final Office Action mailed Jan. 17, 2013, 8 pgs.
- “Roxane Laboratories, Inc.’s Amended Answer and Affirmative Defenses to Plaintiffs Complaint Regarding U.S. Patent No. 8,234,275”, Exhibit 2, (Apr. 26, 2013), 15 pgs.
- “Roxane Laboratories, Inc.’s Amended Answer, Affirmative Defenses and Counterclaims to Plaintiffs Complaint Regarding U.S. Patent No. 8,263,650”, Exhibit 1, (Apr. 26, 2013), 23 pgs.
- “Answer, Defenses, and Counterclaims”, *Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC*, (United States District Court, District of New Jersey Civil Action No. 13-391 ES-SCM, (Apr. 15, 2013), 22 pgs.
- “Notice of Voluntary Dismissal of Counterclaims Pertaining to U.S. Patent Nos. 7,668,730; 7,765,106; and 7,765,107 (Contained in Counts I, II) Pursuant to Fed. R. Civ. P. 41(a), (c)”, *Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC*, (United States District Court, District of New Jersey Civil Action No. 13-391 ES-SCM, (Jul. 15, 2013), 2 pgs.

\* cited by examiner




FIG. 1

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.